A detailed history of Centiva Capital, LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Centiva Capital, LP holds 7,511 shares of BMRN stock, worth $500,457. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,511
Holding current value
$500,457
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $518,409 - $704,832
7,511 New
7,511 $527,000
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $220,420 - $260,370
2,630 New
2,630 $229,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $21,756 - $25,175
251 Added 12.01%
2,341 $202,000
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $1.84 Million - $2.46 Million
-20,985 Reduced 90.94%
2,090 $203,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $798,212 - $1.07 Million
-9,863 Reduced 29.94%
23,075 $2.39 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $224,132 - $264,452
2,728 Added 9.03%
32,938 $2.79 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $318,800 - $387,351
4,460 Added 17.32%
30,210 $2.5 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $1.91 Million - $2.39 Million
25,750 New
25,750 $1.99 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $2.1 Million - $2.68 Million
-29,301 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $584,477 - $668,118
-7,817 Reduced 21.06%
29,301 $2.26 Million
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $323,786 - $363,579
-4,288 Reduced 10.36%
37,118 $3.1 Million
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $829,951 - $1.01 Million
11,106 Added 36.65%
41,406 $3.13 Million
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $2.2 Million - $2.73 Million
30,300 New
30,300 $2.66 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $171,073 - $232,149
-2,397 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $154,055 - $207,028
2,397 New
2,397 $203,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.